InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-22 | 2026-05-27 | Wong Hing C | Director & Chief Executive Officer | Purchase | 113.9K | $1.41 | $160K | 615.8K | View ↗ | |
| 2026-05-22 | 2026-05-27 | GARRETT SCOTT T | Director | Purchase | 177.9K | $1.41 | $250K | 203.4K | View ↗ | |
| 2026-05-22 | 2026-05-27 | Byam Rebecca | Chief Financial Officer | Purchase | 14.2K | $1.41 | $20K | 57.2K | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenues | $54K-97.9% | $2.6M-9.7% | $2.8M-57.7% | $6.7M | $0 |
| Cost of revenues | -$43K+97.3% | -$1.6M+29.5% | -$2.3M+44.8% | -$4.1M | $0 |
| Net revenues | $11K-98.9% | $959K+71.2% | $560K-78.3% | $2.6M | $0 |
| Research and development | $5.4M-14.8% | $6.4M-16.8% | $7.7M-17.8% | $9.3M+14.2% | $8.2M |
| General and administrative | $7.7M+13.0% | $6.8M+0.5% | $6.8M-18.6% | $8.3M+60.3% | $5.2M |
| Legal expenses (recoveries), net | -$1.5M-109.2% | $15.9M | — | — | — |
| Impairment of Long-Lived Asset | $1.5M | $0 | — | — | — |
| Nonoperating loss | $0-100.0% | $1.3M | — | — | — |
| Total operating expenses | $13.2M-56.7% | $30.4M+15.7% | $26.3M+48.8% | $17.7M+32.1% | $13.4M |
| Loss from operations | -$13.2M+55.3% | -$29.5M-14.5% | -$25.7M-70.6% | -$15.1M-12.8% | -$13.4M |
| Interest expense | -$845K-29.2% | -$654K-131.2% | -$283K-123.5% | -$127K | $0 |
| Change in fair value of investment | -$273K | $0 | — | — | — |
| Change in fair value of contingent liability | $1.1M | $0 | — | — | — |
| Loss on sale of put shares | -$264K | $0 | — | — | — |
| Gain on extinguishment of liability | $5.5M | $0 | — | — | — |
| Other income, net | $68K-21.4% | $87K-91.4% | $1.0M+230.1% | $305K | — |
| Net loss | -$8.0M+73.5% | -$30.0M-20.1% | -$25.0M-67.7% | -$14.9M-15.8% | -$12.9M |
| Equity dividend to investor | -$14.3M | $0 | — | — | — |
| Net loss attributable to Common Stockholders | -$22.3M+25.7% | -$30.0M | — | — | — |
| Net loss per share, basic | -$10.63+65.7% | -$30.96-4322.9% | -$0.7-66.7% | -$0.42+39.1% | -$0.69 |
| Net loss per share, diluted | -$10.63+65.7% | -$30.96-4322.9% | -$0.7-66.7% | -$0.42+39.1% | -$0.69 |
| Weighted-average shares outstanding, basic | $2.1M+116.3% | $970K-97.3% | $35.9M+0.3% | $35.8M+90.8% | $18.8M |
| Weighted-average shares outstanding, diluted | $2.1M+116.3% | $970K-97.3% | $35.9M+0.3% | $35.8M+90.8% | $18.8M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
HCW Biologics takes back rights to commercial-ready reagents
HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen
E.F. Hutton & Co. Serves as Sole Placement Agent on HCW Biologics Inc. $4.0 Million Private Placement
HCW Biologics Inc. Announces Pricing of Approximately $4.0 Million Private Placement Offering At-the-Market Under Nasdaq Rules